Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Affymax Inc (AFFY)  
$0.00 0.00 (0.00%) as of 4:30 Tue 4/23


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 37,490,000
Market Cap: 26.24(K)
Last Volume: 125 Avg Vol: 35,949
52 Week Range: $0.0002 - $0.0044
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 225
  Page 3 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-10-02 4 OE $7.99 $4,059 D/D 508 25,502     -
   Orwin John A CEO   •       •      –    2012-10-01 4 AS $21.04 $244,737 D/D (11,632) 92,000     -
   Orwin John A CEO   •       •      –    2012-10-01 4 OE $5.83 $76,730 D/D 11,632 103,632     -
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-09-21 4 AS $22.00 $92,400 D/D (4,200) 24,994     -
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-09-21 4 OE $10.99 $58,689 D/D 4,200 29,194     -
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-09-19 4 AS $20.82 $293,502 D/D (14,062) 24,994     -
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-09-19 4 OE $5.83 $90,755 D/D 14,062 39,056     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-09-17 4 AS $20.75 $138,269 D/D (6,662) 14,039     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-09-17 4 OE $6.23 $96,585 D/D 6,662 20,701     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-09-13 4 AS $20.00 $393,260 D/D (19,663) 14,039     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-09-13 4 OE $18.84 $353,250 D/D 18,750 33,702     -
   Orwin John A CEO   •       •      –    2012-09-13 4 AS $20.00 $979,940 D/D (48,997) 92,000     -
   Orwin John A CEO   •       •      –    2012-09-13 4 OE $5.83 $325,774 D/D 48,997 140,997     -
   Duliege Anne-Marie Chief Medical Officer   •       –      –    2012-09-13 4 AS $20.00 $464,540 D/D (23,227) 32,829     -
   Duliege Anne-Marie Chief Medical Officer   •       –      –    2012-09-13 4 OE $4.36 $140,510 D/D 23,227 56,056     -
   Cross Herb Chief Financial Officer   •       –      –    2012-09-05 4 AS $18.50 $92,500 D/D (5,000) 11,293     -
   Cross Herb Chief Financial Officer   •       –      –    2012-09-05 4 OE $7.99 $39,950 D/D 5,000 16,293     -
   Orwin John A CEO   •       •      –    2012-08-20 4 AS $17.50 $857,430 D/D (48,996) 92,000     -
   Orwin John A CEO   •       •      –    2012-08-20 4 OE $5.83 $325,767 D/D 48,996 140,996     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-08-20 4 AS $17.50 $377,423 D/D (21,567) 14,952     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-08-20 4 OE $6.23 $145,393 D/D 18,750 36,519     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-08-15 4 AS $16.48 $75,531 D/D (4,584) 17,769     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-08-15 4 OE $6.23 $36,098 D/D 4,584 22,353     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-08-13 4 AS $15.95 $74,311 D/D (4,659) 17,769     -
   Orwin John A CEO   •       •      –    2012-08-01 4 AS $16.31 $17,941 D/D (1,100) 92,000     -
  225 Records found
  1  2  3  4  5  6  7  8  9   
  Page 3 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us